Hangzhou Just Biotherapeutics lands $35 mln
China-based Hangzhou Just Biotherapeutics, a biotherapeutics platform company, has closed $35 million in Series B+ financing. Hillhouse Capital led the round with participation from return backers Temasek, Lilly Asia Ventures, ARCH Venture Partners, Taikang and BOCGI Zheshang Capital.
6 June 2018•1 min read
